Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis

Area of Science:

• Neuroscience
• Immunology
• Biochemistry

Background:

• Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Alterations in circulating catecholamines and indolamines have been suggested in MS patients.
• Natalizumab is an established therapy for relapsing-remitting MS (RR-MS).

Purpose of the Study:

• To investigate the impact of natalizumab on circulating catecholamine and indolamine levels in RR-MS patients.
• To explore the potential relationship between these neurotransmitters and MS.
• To assess the therapeutic effects of natalizumab on specific biochemical markers.

Main Methods:

• A cohort of 12 RR-MS patients and 12 healthy controls was studied.
• Patients received natalizumab (300 mg) for 56 weeks.
• Serum and plasma levels of melatonin, dopamine, epinephrine, norepinephrine, and oxidative stress markers were measured at baseline and after treatment.

Main Results:

• Epinephrine and dopamine levels were lower in RR-MS patients at baseline compared to controls and did not normalize with treatment.
• Melatonin levels, initially decreased in RR-MS patients, returned to normal with natalizumab therapy.
• Norepinephrine levels, elevated in RR-MS patients, decreased to control levels after natalizumab treatment.

Conclusions:

• Natalizumab effectively normalized altered melatonin and norepinephrine levels in RR-MS patients.
• The study suggests a potential role for natalizumab in modulating neurotransmitter balance in MS.
• These findings contribute to understanding the neurochemical effects of natalizumab in MS management.